SCHEMBL31748662

SCHEMBL31748662

COC(=O)c1cn(COCC[Si](C)(C)C)c2cc(F)c(Cl)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 7/20 0.38
▸ LMNA P02545 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ PTPN1 P18031 1/20 0.33
▸ KLKB1 P03952 2/20 0.33
▸ EGFR P00533 1/20 0.33
▸ IGF1R P08069 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ FLT4 P35916 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ EPHB4 P54760 1/20 0.33
▸ TEK Q02763 1/20 0.33
▸ NR4A2 P43354 1/20 0.31
▸ KEAP1 Q14145 1/20 0.31
▸ NFE2L2 Q16236 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ P2RX7 Q99572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31748342 0.90 KEAP1 (0.41) DGAT1LMNAPTPN1KLKB1EGFR
SCHEMBL31748492 0.89 DGAT1 (0.35) DGAT1MAPTPTPN1KLKB1EGFR
SCHEMBL31748486 0.80 DGAT1 (0.33) DGAT1PTPN1EGFRIGF1RSRC
SCHEMBL31748668 0.78 DGAT1 (0.33) DGAT1EGFRIGF1RSRCFLT4
SCHEMBL31748692 0.77 DGAT1 (0.34) DGAT1LMNAMAPTPOLBNPSR1
SCHEMBL26620077 0.76 MAPT (0.36) DGAT1MAPTSMN1; SMN2NPC1F11
SCHEMBL30296702 0.76 MAPT (0.36) DGAT1MAPTSMN1; SMN2NPC1F11
SCHEMBL30540656 0.73 DGAT1 (0.36) DGAT1KLKB1F11
SCHEMBL17782347 0.72 NR4A2 (0.62) LMNAMAPTPOLBNPSR1NR4A2
SCHEMBL31748415 0.72 HDAC6 (0.33) KLKB1EGFRIGF1RSRCFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF BIOLEXIS THERAPEUTICS INC (US) 2025-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF PRKAB2, PRKAB1, PRKAR2B DGAT1 3043/4885LMNA 1767/4885MAPT 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback